NCT06810934View on ClinicalTrials.gov

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

September 30, 2029

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

CoTend-BXBB (SARS2-30404)

Ad35-vectored SARS-CoV-2 RBD (XBB.1.5) vaccine

BIOLOGICAL

CoTend-s3BXBB (SARS2-17032)

Ad35-vectored s3-SARS-CoV-2 RBD (XBB.1.5) vaccine

BIOLOGICAL

Placebo

Sterile sodium chloride 0.9% for injection, preservative free

Trial Locations (2)

90095

RECRUITING

UCLA Westwood, Los Angeles

94110

RECRUITING

UCSF Community and Clinical Research Center, San Francisco

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

University of California, Davis

OTHER

collaborator

Tendel Therapies, Inc.

UNKNOWN

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Kara Chew

OTHER

NCT06810934 - A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses | Biotech Hunter | Biotech Hunter